Story perspectives

Cartesian Therapeutics Grants Stock Options to New Hires

1/7/2026

Summary

Story summary

Cartesian Therapeutics, Inc. announced inducement awards for two new employees on January 2, 2026.
The company granted options to purchase 7,350 shares of common stock at an exercise price of $6.76, the closing price on the grant date.
The options will vest 25% on January 2, 2027, with the remainder vesting monthly over three years, fully vesting by January 2, 2030.
Cartesian Therapeutics specializes in cell therapy for autoimmune diseases, with its lead asset, Descartes-08, in Phase 3 clinical development for generalized myasthenia gravis.

1 of 1

Story summary

Cartesian Therapeutics, Inc. announced inducement awards for two new employees on January 2, 2026.
The company granted options to purchase 7,350 shares of common stock at an exercise price of $6.76, the closing price on the grant date.
The options will vest 25% on January 2, 2027, with the remainder vesting monthly over three years, fully vesting by January 2, 2030.
Cartesian Therapeutics specializes in cell therapy for autoimmune diseases, with its lead asset, Descartes-08, in Phase 3 clinical development for generalized myasthenia gravis.